Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy Regimens in Stage II or III Rectal Cancer
NCT00068692Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2003
- Primary completion
- Nov 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in rectal cancer, sponsored by National Cancer Institute. Started Oct 2003; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00068692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068692.